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Background The performance of cervical cancer (CC) screening can be improved by combining
Pap smear with human papillomavirus (HPV) testing or visual methods, addressing local
demographic, clinical and economic characteristics.
Objectives To examine the performance of standalone and combined screening tools in populations
with variable prevalence of cervical intraepithelial neoplasia (CIN) and CC.
Methods Merged data-sets from the Latin American Screening Study and New Independent States
cohorts provided results for 15,000 women, screened using Pap smear, HPV testing and visual
inspection with acetic acid, in Brazil, Argentina, Russia, Belarus and Latvia. Bayesian correction for
verification bias was used.
Results At CIN2þ cut-off, HPV detection alone was the most sensitive technique. There was an
improvement (88.5% to 92.7%) in Hybrid Capture 2 (HC2) sensitivity among women 35 years
old. Using HPV detection alone was the least specific screening tool, regardless of the age group
(69.9% [95% CI 66.5–72.8%] and 86.4% [95% CI 84.6–88.2%], in , or 35 years,
respectively). Of the test combinations, Pap smear (LSIL threshold) with HC2 had the highest
specificity (98.7%; 95% CI 98.3–99.0%). However, in women 35 years, the sensitivity of Pap
alone was superior to that of the combination.
Conclusions The Pap test is a highly specific screening option in populations with medium-range CC
prevalence. Combined testing for HPV in this scenario may yield slightly better positive predictive
values in women 35 years of age with LSIL, but at a high incremental cost.
INTRODUCTION
D
espite the success of organized Pap test-based
screening programmes in reducing the burden of
cervical cancer (CC) in many privileged countries,
inherent limitations of the test preclude complete control
of CC even in countries with well-implemented screening
programmes.1,2 Some countries with economic and logistical
shortcomings have been unable to exploit the full potential
of cervical cytology screening, and continue to deal with a
substantial disease burden.3
There are limitations to the Pap test. The full implemen-
tation of such a screening programme requires a well-
structured and costly network of health services, including
sample collection sites, processing and reading laboratories,
centralized cancer registry and professional staff to convey
results to the screened population. Facilities to treat detected
CC and precursor lesions are also costly.4 The Pap test itself
has limited sensitivity (40–50% even in best laboratories),
necessitating repeat screening at relatively short intervals
(2–3 years).4 Verification of positive results using colpo-
scopy and biopsy necessitates additional visits.4,5
The technical shortcomings of cervical cytology led to the
failure of many countries to reduce their CC burden, but
have also prompted the development of alternative and/or
adjunct screening methods, such as human papillomavirus
(HPV) testing, visual inspection with acetic acid (VIA) and
combinations of these tests. Results from most large
trials suggest that screening performance can be improved
with such combinations. Combinations of screening tests
are usually trialled either sequentially (referral to colpos-
copy when screen positive in both tests) or in parallel (colpo-
scopy performed when one test is positive). Sequential
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combinations generally yield high specificity at the expense
of sensitivity; the reverse is true for parallel testing.
However, these improvements seem to be critically depen-
dent on local circumstances and availability of resources.
Based on an encouraging experience from the USA,6 the
Food and Drug Administration (FDA) recently approved
the use of HPV testing with Hybrid Capture 2 (HC2) in com-
bination with the Pap test for screening women over 30
years old. This strategy aims to maximize the high sensitivity
of the HPV test and the almost 100% specificity of the Pap
test. By contrast, in low-resource settings like India,
researchers advocate the use of VIA as the primary CC
screening tool, with advantages over the Pap test such as
the ‘see and treat’ possibility. However, when tested in
other settings (e.g. Latin America), VIA was not particularly
valuable, because of its low specificity and low positive pre-
dictive values in populations with moderate to low preva-
lence of CC and its precursors.7,8
We evaluated the performance of different screening tests
compared with conventional and liquid-based cervical
cytology in two trials, the New Independent States (NIS)
Cohort and the Latin American Screening Study (LAMS),
from Russia, Belarus and Latvia, and Brazil and
Argentina.9,10 These trials were designed to compare the
performance of several screening tools in populations with
variable prevalence of CIN and CC and with different facili-
ties to conduct organized screening. The standardized struc-
ture and test quality of the two studies, along with
comparable epidemiological characteristics of the women
in the two cohorts, allowed us to pool the data-sets to
create a combined cohort of over 15,000 women. We then
assessed the performance of different standalone screening
tests and multiple sequential combinations of these tests in
the detection of CC and its precursor lesions. We have also
produced simulations based on the data, and summarize
the available information on the optimal screening strategy
for CC in each setting.
SUBJECTS ANDMETHODS
Participants
The analysis is based on a combined sample of 3187 women
from the NIS study, and 12,114 women in the LAMS studies.
Both studies were international multicentre trials testing
optional screening tools in low-resource settings of three
NIS countries (Russia, Belarus and Latvia)11 and in two
Latin American countries (Brazil and Argentina).9 Both
studies shared similar patient accrual, data collection
methods and test standards, facilitating the data merger.
Cytology was universal for all women; the number of
women screened with each of the other tests varied for logis-
tic and budgetary reasons (see Table 2).9,11
The 3187 women in the NIS study cohort attended six
outpatient clinics between 1998 and 2002. This study
sample comes from three distinct backgrounds: (i) women
participating in CC screening; (ii) women attending gynae-
cology outpatient clinics; and (iii) women examined at sexu-
ally transmitted disease clinics. The mean age at enrolment
was 32.6 (+10.7 SD) years (median 30.6, range 15–85
years).11 All eligible women underwent a Pap smear and
were tested for HR-HPV using HC2 assay. The first 1500
women were also tested with polymerase chain reaction
(PCR) and confirmative hybridization. Patients with
ASC-US or higher Pap had biopsy confirmation at baseline.11
The LAMS study combined a population-based, cross-
sectional study and a prospective cohort study of women
in regions with different (low, intermediate, high) incidence
of CC in Brazil and Argentina.9 In the first phase (the orig-
inal LAMS Study cohort), the four clinics examined 12,114
women between February 2002 and June 2003. Mean age
at enrolment was 37.9 years (range 14–67; median 37.7
years). In this trial, eight different diagnostic tests were com-
pared. Cervical cytology (conventional and liquid-based
cytology [LBC]) was compared (1) with four optional
screening tools suggested for low-resource settings (a) VIA,
(b) visual inspection with Lugol iodine (VILI), (c) cervicogra-
phy, and (d) screening colposcopy; and (2) with the new
molecular diagnostic tools (HPV testing by HC2), performed
(a) in samples collected by physicians, and (b) in those taken
by self-sampling devices.12,13 Women testing positive with
any of these techniques were examined by colposcopy at
the second visit. In addition, a 5% random sample of all test-
negative (Pap, VIA, VILI, HC2) women was submitted to col-
poscopy to assess false-negative exams, and 20% of baseline
HC2-negative women were referred for new HC2 to assess
the rates of incident HPV infections.
Tests and test providers
Screening tests were performed by trained professionals. In
both studies, epidemiological data were obtained by
doctors with formal training and previous expertise in obste-
trics and gynaecology. Screening tests were performed by
the same professional who collected the clinical and epide-
miological data (patient history).
Cervical cytology (Pap test)
In the NIS study, all women were examined using conven-
tional Pap smear only,11 whereas in the LAMS study, three
methods were used: conventional Pap and two different
LBC techniques (DNA-Citoliqw; Digene Brazil, Sao Paulo,
Brazil and SurePathw; TriPath, Durham, NC, USA). In our
analysis we have used only the results of the conventional
Pap test, which were available from all patients of the com-
bined NIS-LAMS cohort. Results from the LAMS study were
classified using the Bethesda System of 2001 (TBS 2001).
Modified Papanicolaou classification was used for the NIS
study, subsequently transformed to TBS 2001 to enable
joint analyses.
Other screening tests
The technical aspects pertaining to VIA and VILI, cervicogra-
phy, detection of HPV DNA with HC2 assay, and detection
and quantification of HR-HPV genotypes by realtime PCR
have been described in full detail in previous reports from
the LAMS and NIS study groups.9 –13
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Directed punch biopsy
Directed punch biopsies (and cone biopsies) were fixed in
formalin, embedded in paraffin and processed into
5-mm-thick haematoxylin–eosin-stained sections for light
microscopy, following the routine procedures. All biopsies
were examined in the Pathology Departments, and diag-
nosed using the commonly agreed CIN nomenclature. For
the study purposes, the pathologists were also asked to
notify the morphological changes suggestive for the pres-
ence of HPV in cases with no CIN, i.e. HPV-NCIN (¼flat
condyloma).
Statistical analysis
All data analyses were performed with the R environment
for statistical computing14 and using 95% confidence inter-
vals (95% CI) and P ¼ 0.05 throughout. We defined arbi-
trary thresholds for Pap tests (atypical squamous [ASC] or
higher, low-grade squamous intraepithelial lesion [LSIL]
or higher, high-grade squamous intraepithelial lesion
[HSIL]), and used the customary 1 relative light unit
threshold for HC2. VIA was considered positive when the
image, second to the examiner subjective assessment, was
classified as suggestive of condyloma, cervical intraepithelial
neoplasia (CIN) 1, CIN 2, CIN 3 or cancer.7 We then calcu-
lated the number of expected colposcopies after each test or
combination of tests (a positive test ¼ colposcopy), and cal-
culated the ratio of performed:expected colposcopies for
each case (¼verified positives). We considered the disease-
free women who (1) had all tests negative; (2) had one or
more tests positive but had a normal colposcopy and/or
normal biopsy result. Test combinations were considered
positive when both screening tests were positive (sequential
testing). We then calculated the number of prevalent
CIN1þ or CIN2þ lesions detected using the defined
thresholds for each test or test combination. We calculated
the performance indicators (sensitivity, specificity, positive
[PPV] and negative [NPV] predictive values) with standard
formulae, and used generalized formulae for verification
bias correction, according to Begg and Greenes15 and
Gray et al.16
The entire cohort was divided into two groups, ‘verified’
and ‘non-verified’. The empirical probability of verification
(i.e. receiving the gold standard test) was calculated for
each test result category. Within each test result category,
the observed frequency counts among verified patients
were divided by the empirical probability to obtain
unbiased estimates of the frequency counts in perfect
study design, i.e. in a setting where all patients received
the gold standard test.
The final corrected sensitivity was obtained with the fol-
lowing relation:
Corrected sensitivity
¼ v11 4 ½ðv11 þ v12Þ 4 n1
v11 4 ½ðv11 þ v12Þ 4 n1 þ v21 4 ½ðv21 þ v22Þ 4 n2
;
where v11 ¼ diseased verified women with ‘positive’ test; v12
¼ verified non-diseased women with ‘positive’ screening
test, v21 ¼ verified diseased women with ‘negative’ screen-
ing test; v22 ¼ verified non-diseased women with ‘negative’
screening test; n1 ¼ total number of women with ‘positive’
screening tests; n2 ¼ total number of women with ‘normal’
screening tests. Corrected specificity was calculated likewise.
Confidence intervals were constructed using bootstrap
re-sampling methodology. Two thousand replications were
performed for each calculation to ensure consistent
asymptosy.
RESULTS
Table 1 lists the main epidemiological and demographic
characteristics of the women enrolled in the LAMS and
NIS studies. The mean age at enrollment was slightly
higher (37.8 versus 32.5 years) for the women in the
LAMS study compared with women in the NIS cohort.
Considering both studies together, around two-thirds of
the women were aged 25–50 years. Most (72%) women
started their sexual activity at the age 17þ years, and
approximately the same proportion were living with a
partner at the time of the interview. In the NIS cohort, the
proportion of women reported to have started sexual activity
before 14 years of age was lower (1.2% versus 8.8%) than
that in the LAMS cohort. Nulliparous women comprised
more than 40% of the sample in both studies, while
approximately 21% of the women in the LAMS cohort
had three or more offspring, compared with only 3.0% in
women of the NIS cohort.
Table 1 Key epidemiological and clinical characteristics of
the women
Region of origin No. (%) Study
LAMS
Buenos Aires (Argentina) 3437 (22.46) LAMS
Porto Alegre (Brazil) 3043 (19.89) LAMS
São Paulo (Brazil) 3000 (19.60) LAMS
Campinas (Brazil) 2634 (17.2) LAMS
Novgorod (Russia) 1088 (7.11) NIS
Moscow (Russia) 1062 (6.94) NIS
Minsk (Belarus) 590 (3.85) NIS
Riga (Latvia) 447 (2.92) NIS
LAMS NIS
No. (%) No. (%)
Total 12114 (79.2) 3187 (20.8)
Age (years)
Mean (SD) 37.8 (11.2) 32.5 (10.7)
18–20 385 (3.2) 364 (11.4)
21–35 4601 (38.0) 1638 (51.4)
36–50 4907 (40.6) 1009 (31.7)
Above 50 2204 (18.2) 176 (5.5)
Onset sexual activity
14 or younger 1063 (8.8) 36 (1.2)
15–16 2667 (22.1) 403 (14.0)
17–19 4702 (39.0) 1328 (46.0)
20 and older 3638 (30.1) 1118 (38.8)
Marital status
Single 3814 (31.6) 760 (26.6)
Living with partner 8270 (68.4) 2096 (73.4)
Parity
Zero 5021 (41.5) 1163 (40.5)
One 2331 (19.3) 1030 (35.9)
Two 2109 (17.4) 590 (20.6)
Three or more 2635 (21.8) 86 (3.0)
LAMS, Latin American Screening Study; NIS, New Independent States
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Table 2 gives detail on the data from which the perform-
ance figures for the different screening tests were calculated.
The proportion of positive tests verified with colposcopy
ranged from 52% for PCR to 99.3% for women who had
a positive VIA associated with ASC, or higher. As per
study design, colposcopy was performed at the same visit
as VIA or VILI, yielding high positive verification
proportions (see discussion). Among women with no VILI
or VIA, the verification of positive screening modalities
was on average 76% in the whole cohort and almost 78%
in women aged 35 years or older. The number of CIN1þ
and CIN2þ detected for each screening strategy is
also displayed.
Table 3 shows the corrected and uncorrected perform-
ance of the different standalone and combined screening
strategies, having CIN2þ as the screening endpoint
(cut-off). HPV detection used alone (by HC2 or PCR) was
the most sensitive technique. There was a slight improve-
ment (88.5–92.7%) in HC2 sensitivity in women 35
years of age. After Bayesian correction, the HPV detection
techniques sustained their superiority in terms of sensitivity
(for HC2, 79.0% [95% CI 71.2–86.8%] in women ,35
years and 85.1% [95% CI 78.4% to 91.8%] in those 35
years). HPV detection, when used alone, was also the
least specific screening tool, regardless of the age group
(69.9% [95% CI 66.5–72.8%] and 86.4% [95% CI 84.6–
88.2%], after correction, in each age stratum). However,
in women above 35 years of age, when combined with
the Pap test, at both ASC and LSIL thresholds, good bal-
ances between sensitivity and specificity were obtained
(corrected sensitivity [LSIL þ HC2] ¼ 44.8% [95% CI
38.1–51.6%], specificity ¼ 98.6 [98.3–99.0%]). Of the
test combinations, that of Pap smear (LSIL threshold) with
HC2 was the best option in terms of specificity (98.7%
[95% CI 98.3–99.0%], after correction). However, in this
age stratum, Pap alone performed almost similarly in
terms of specificity (98.2%2[95% CI 97.8–98.6%], after
correction), but used alone had higher sensitivity than
when combined with HC2 (54.8% [95% CI 47.9–61.9%]
alone versus 44.8% [95% CI 38.1–51.5%] when com-
bined). This loss in sensitivity among women 35 years
is counter-balanced by a gain in PPV (47.9% alone versus
61.1% when combined). In women ,35 years, the combi-
nation of Pap (LSIL threshold) and HC2 yielded a corrected
sensitivity of only 22.7% (95% CI 15.3–30.2%), compared
with 32.8% (95% CI 24.4–40.3%) for Pap (LSIL) alone.
However, the gain in PPV observed when combining Pap
and HC2 in women 35 years was not observed in the
younger age stratum: 29% for Pap (LSIL) alone versus
29.7% for Pap and HC2 combined. Using a higher
threshold for Pap (HSIL) resulted in unacceptably low cor-
rected sensitivity in women ,35 years (12.7%; 95% CI
7.4–18%). This figure was better in women 35 years
(29.2%; 95% CI 22.8–35.5%), but still much lower than
that obtained with less aggressive Pap thresholds (LSIL or
ASC). By contrast, intermediate values of sensitivity and
specificity were obtained with VIA. While combined with
Pap tests or HC2, the improvement in specificity was
counter-balanced by losses in sensitivity and PPV. Except
for VIA, all screening strategies were more accurate, with
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DISCUSSION
Our study represents a major attempt to evaluate alternative
strategies for CC screening in low- and middle-resource set-
tings. In general terms, comparing several standalone and
combined screening strategies, HC2 was by far the most sen-
sitive tool, whereas the Pap test was highly specific at the
LSIL threshold in diagnosing CIN2þ. However, our results
must be interpreted in the light of the variable screening
options and epidemiological peculiarities of the screened
populations. For instance, combining HC2 and the Pap test
at ASC threshold resulted in a well balanced option for
women 35 years, whereas this option was unacceptably
non-specific among younger women. Overall, for the
studied population, the PPV of the visual tests (VIA, VILI)
was also unsatisfactory, largely due to the relatively low
prevalence of CIN. In a previous report on women screened
in the LAMS study, we detected a similar trend in the per-
formance indicators, although the corrected figures are not
directly comparable because the method used for verifica-
tion bias correction was different in these two studies.17
The most convenient method for assessing the population
effectiveness of a screening is programme sensitivity.17
However, programme sensitivity is dependent on the sensi-
tivity of the screening test (or the combination of tests),
together with the compliance with further follow-up and
diagnostic work-up (verification), and the natural history
of disease.18 However, sensitivity alone does not cope with
the other important requirements of a screening pro-
gramme, most notably the impact of false-negatives in the
screening, the effects of over-screening, and the medical
and legal consequences of false-positives.19 Bearing this in
mind, we compared our cohort with other recent major
studies to assess the potential implications of these different
data. For instance, our corrected specificity estimate for the
Pap test (LSIL and ASC thresholds) (98.8%) is higher than
that (82.1%) reported in studies with comparable design
conducted in the USA.20,21 These differences highlight the
importance of considering the disease dynamics in the
screened population. In the two US studies, the prevalence
of CIN2þ was as low as ,1%, whereas in our combined
LAMS-NIS cohort, 303 CIN2þ cases were found among
15,301 women (1.9%), but considering that on average
75% of the positive tests were verified, we can estimate a
2.5% true prevalence of CIN2þ in the entire population.
Mathematical dissimilarities in the verification bias correc-
tion procedures between the two studies, combined with
differences in accuracy in the interpretation of the Pap
tests, may all have contributed to the observed differences.
Correction for verification should be a major concern in
cross-sectional exam validity studies with incomplete
designs. We chose the Bayesian approach to estimate the per-
formance indicators because this method may be the most
appropriate when the number of verified negatives is very
low.15,16 In our study, the percentage of verified negatives
only rarely surpassed 5% (e.g. for VIA). In a previous
report17 using the algorithm for verification bias correction
proposed by Reichenheim and Ponce de Leon,22 the corrected
sensitivity of the Pap smear (HSIL threshold) in detecting
CIN2 or worse in women above 35 years of age was only
17.2% (95% CI 13.8–20.6%), in contrast to the uncorrected
figure (67.4%; 95% CI 56.8–76.8%). The mathematical
output of this type of correction method seems to heavily
underestimate the sensitivity of the test when there is a
small proportion of verified negatives, although this effect is
less marked for the specificity of the test.
In a recent meta-analysis of 25 studies with comparable
study subjects (women aged 18–70 years, participating in
CC screening programmes, not previously followed-up for
cytological abnormalities), types of interventions (HPV
tests þ cytology) and verification of disease status (colpo-
scopy and/or biopsy on at least all Pap smear or HPV test
positives),23 the sensitivity of HPV testing was higher than
that of cytology even at the ASC threshold, whereas the
specificity was significantly higher for cytology at the
threshold of LSIL. This advantage was much less obvious
at the ASC cut-off. In our study, we detected similar levels
in sensitivities of these two tests, but our cytology was far
more specific than HPV test at both ASC and LSIL
thresholds, before correction for verification bias. After cor-
rection, our estimated specificity for HC2 is closer to the
figures from the meta-analysis, highlighting the importance
of using appropriate mathematical corrections when the
gold standard is not applied to the women with negative
screening test results (i.e. those considered a priori true nega-
tives). In this meta-analysis, the pooled specificity of HC2
was 90.4% (95% CI 87.1–93.6%) for CIN3, while we
obtained a corrected specificity of 86.4% (95% CI 84.6–
88.3%) among women 35 years of age. All our estimates
were made using CIN2þ as the screening endpoint.
By contrast, our experience with the visual inspection
techniques (VIA, VILI) was far less encouraging than the
Indian and African experience.5,8 This is probably due to
the marked contrasts between the Indian and Sub-Saharan
populations and the LAMS-NIS cohort in prevalence of
CIN2þ lesions (high in the former, intermediate in the
latter). Another possible interpretation of this reduced per-
formance, as compared with that described in other publi-
cations, is that differences in test standardization might
have been responsible for a large number of false-positives.
Our corrected performance indicators for VIA were favoured
by the almost perfect verification of the VIA-positive cases,
resulting in only minor corrections in sensitivity (down-
wards) and specificity (upwards). These tests allow for
immediate confirmation of the findings in settings where
colposcopy is available at the screening site or nearby.8 In
our setting (LAMS), this was relevant. Despite efforts to
obtain colposcopy confirmation of all screen-positive
women, we were able to verify only approximately 75% of
these. This number was much lower for PCRþ women
(below 50%) (PCR done only for a small fraction of
women, as a supplement to HC2), which resulted in more
marked deviation in the performance figures obtained
after correction for verification bias. In clinical practice, the
failure to provide the results of Pap test and HPV assay
immediately is a potential shortcoming, especially in low-
resource settings, where patient compliance is a problem,
and many women never return to obtain their test results.
The logical next step should be to combine the Pap test
(with low sensitivity but high specificity) with HPV DNA
testing, with high sensitivity but lower specificity,23 to
create a screening strategy that should cope with the
known inherent problems of the standalone tests. Many
reports advocating the feasibility of this strategy have been
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published.17,20,21 Meta-analysis of the pooled data from
these studies, however, suggests that while the combined
use of Pap test and HPV DNA assay has the highest sensi-
tivity, it also has the lowest specificity.23 In our study we
did not consider screening test combinations where a posi-
tive test in only one of the two tests resulted in colposcopy
referral. In our previous reports,7,17 we tested those
options, with unsatisfactory results in specificity as an
outcome, thus confirming the data of the meta-analysis.
Also other recent studies have assessed the possibility of
referring for colposcopy all women who test positive for
HC2 or ASC-US,20 reporting excellent sensitivity but unac-
ceptably low specificity. This suggests that adding HPV
DNA testing to cytology increases the sensitivity of the
latter, but will seriously compromise the high specificity of
the Pap test. However, repeat positive HC2 is an
FDA-approved recommendation for colposcopy in the
USA, because repeat ASC mandates colposcopy in several
countries. We could not evaluate these repeat test options
in our combined cohort, because most women were
excluded from the prospective follow-up after a normal
colposcopy.
The explanation for this unexpected result of the pooled
data for Pap and HPV test combinations is the different per-
formance of the tests in different age groups, emphasizing
that screening strategies for young women should be differ-
ent from those for older women.17 This was confirmed in
our recent report, where all standalone tests and combined
HC2 and Pap performed significantly better among older
(.35 years of age) women, using the one-of-two test posi-
tive option.16 In our present analysis, co-testing positive
with HC2 and Pap smear did not efficiently improve the
overall specificity of the combination, as shown in other
studies.20,21 Also, we did not test the combination of HC2
and Pap test at the HSIL threshold, because most women
with HSIL also test HPV-positive. Among younger women,
the Pap test (LSIL threshold) was far more sensitive as a
standalone test in detecting CIN2þ than when combined
with HC2, and the gain in specificity was minimal for the
combination. As expected from our previous report,17 all
standalone tests and test combinations showed better per-
formance in the subcohort of women 35 years of age,
and the marked difference between Pap alone and the
Pap–HC2 combination seen in younger women almost dis-
appeared in the older women. In the economic context of
the LAMS-NIS countries, the addition of HPV testing
without significant gains in performance would not be
advisable. Moreover, if such a test combination results
in increased referral for colposcopy, incremental costs
would arise. The only (mathematical) advantage derived
from the co-testing with HC2 and Pap smear was that our
simulations yielded better PPVs than those of either test
used alone. These improved PPVs could prove to be
particularly meaningful in a screening setting, because an
optimal screening test should have the highest possible
PPV, i.e. to detect only positive lesions with no (or little)
need for other confirmatory tests that would result in incre-
mental costs.24
Co-testing with HC2þ and ASCþ was clinically the most
advantageous combination in the simulations performed.
Because the proportion of verified positives for HC2 and
ASCþ was quite similar in all age strata, we may consider
the corrected performance figures without having to take
into account distortions caused by dissimilarities in verifica-
tion ratios (i.e. groups with lower positive verification ratios
would display lower values of sensitivity and higher
specificity after correction). Our results also indicate that
co-testing with HPV testing and Pap smear may be advisa-
ble only in settings where the prevalence of HPV is rela-
tively low and where economic resources are not
constrained. In our study populations neither of these con-
ditions applies, and we found that co-testing with HC2 and
Pap smear was advantageous only in women 35 years of
age with ASC. HPV testing would also be advantageous for
women 35 years of age with LSIL, because of an
increased PPV of this test combination compared with that
of the Pap test alone. We also detected that in our
context, where the prevalence of disease is not as high as
it is in some previously studied African and Indian popu-
lations, the main advantage of VIA (i.e. the possibility of
immediate confirmation of positive test results) brings
little relief to the unacceptably low PPV of this test, relative
to the other options.
Our results may be valuable for health-care planners in
medium-resource countries. In these contexts, the use of
HPV testing as a screening tool may not be advisable,
except in a few specific situations. In most instances, due
to the high prevalence of HPV even among women 35
years of age, the specificity of the HC2–Pap combination
is reduced to unacceptably low levels. The Pap test is a
highly specific option to screen for CC in populations
with a disease prevalence ranking within the medium
global range. In spite of the relatively low sensitivity of
cytology compared with that of, for example, HPV testing,
the protracted natural history of CIN makes repeated rescre-
ening an acceptable option to improve the overall sensi-
tivity of the screening programme. On the other hand,
even small decreases in screening specificity can make the
programme impractical, by dramatically increasing the
demand for confirmatory colposcopy. Co-testing with
HPV in this scenario may yield slightly better PPVs in
women 35 years of age with LSIL, but at a high incre-
mental cost.
Further research should now aim to find the wisest way
to combine the properties of HPV testing and cytology.
Evidence suggests that the use of ASC-US cytology with
HPV testing may avoid a large number of wasteful colposco-
pies.25 The use of LSIL cytologies may also be effective in
reducing the number of unnecessary colposcopies to 50%
in women .35 years of age. Some recent studies also
emphasize the potential role of HPV testing in future
screening scenarios, and there are indications that
one-time HPV-based screening is superior to Pap tests and
VIA for reducing CC mortality.26,27 Although evidence
favoring the use of HPV tests in several screening scenarios
accumulates, a comment from the Discussion section of a
2007 meta-analysis: ‘Caution should be taken to make
sure that these findings (HPV testing in primary screening
improving the control of cervical cancer) are applicable
to all countries’, is still contemporary and valid.23 From
the results of the present study, we cannot advocate
using direct visual inspection (VIA) of the cervix in
screening populations where the prevalence of CIN is not
extremely high.
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